The global tobacco epidemic continues to present one of the most significant public health challenges, with over 7 million deaths annually attributed to tobacco use. As governments and health organizations grapple with this crisis, Tobacco Harm Reduction (THR) emerges as a pragmatic and scientifically supported strategy to mitigate the adverse health effects of smoking for…
We are thrilled to announce the appointment of Phil Hudson as the newest member of the GINN team. Phil will spearhead membership and outreach initiatives across the UK and European markets, bringing a wealth of experience and insight to our mission of advancing tobacco harm reduction and fostering innovation in the novel nicotine industry. A…
The U.S. Food and Drug Administration (FDA) has taken a landmark step in tobacco harm reduction by authorizing the marketing of 20 ZYN nicotine pouch products. This authorization, granted under the Premarket Tobacco Product Application (PMTA) process, establishes a clear regulatory pathway for nicotine pouches, reinforcing their role as a viable alternative for adult smokers…
The growing popularity of nicotine pouches as a smoke-free alternative has positioned them as a pivotal tool in tobacco harm reduction. However, their rapid market growth has also drawn increased regulatory scrutiny, particularly in the European Union (EU). As policymakers deliberate over the future of these products, the question arises: Could nicotine pouches face stricter…
In the evolving landscape of tobacco harm reduction, understanding the factors that influence consumer behavior is critical. Behavioral research plays a pivotal role in shaping strategies to encourage the adoption of reduced-risk products, fostering informed decision-making, and advancing public health objectives. By integrating data-driven insights, researchers and policymakers can better address the complexities of nicotine…